Clinical Trial Update: A Six-month Phase 2 Study of Oral hPTH(1-34) (EBP05) in Postmenopausal Women With Low Bone Mass [Phase 2]

View source ↗

Summary

A completed Phase 2 study evaluating oral hPTH(1-34) (EBP05) in postmenopausal women with low bone mass (osteoporosis).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis

Drugs mentioned

• EBP05 (hPTH(1-34) oral tablet)

Snippet

Sponsor: Entera Bio Ltd. | Conditions: Osteoporosis | Phase 2 | Status: COMPLETED